|
Oct 9
|
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Oct 8
|
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
|
|
Oct 4
|
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
|
|
Jul 31
|
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
|
|
May 15
|
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...
|
|
Mar 22
|
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Q4 2023 Mink Therapeutics Inc Earnings Call
|
|
Mar 21
|
MiNK Reports Fourth Quarter and Year-End 2023 Results
|
|
Jan 30
|
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
|
|
Dec 20
|
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
|
|
Nov 3
|
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
|
|
Nov 3
|
MiNK Therapeutics Insider Ups Holding During Year
|
|
Sep 27
|
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
|